Production of Recombinant Human G-csf: a Techno-economic Analysis

Filgrastim is an important protein that treats neutropenia which has significant clinical applications including a possible cure against cancer. However, despite its significant medical benefits, the large scale production of Filgrastim is still rare and is reported only by a handful of companies throughout the world. We present a techno-economic feasibility analysis for a recombinant human analog of Filgrastim production on a pilot scale that can be emulated for industrial scale production. The current article provides a general business overview with considerable emphasis on a pilot scale venture highlighting its techno economic analysis and competitive advantages.